For more information about the session and speaker, simply click on the session title.
Please note: This page will be updated regularly and is subject to changes.
Part A | |
|---|---|
| 9:00 AM - 9:05 AM | Welcome and introduction |
| 9:05 AM - 10:00 AM | A1. Cancer and cancer therapeutics Rob Berg, Syneos Health, NL |
| 10:00 AM - 11:15 AM | A2. Carcinogenesis & tumor cell biology Jos Jonkers, Netherlands Cancer Institute, NL |
| 11:15 AM - 11:30 AM | Morning Break |
| 11:30 AM - 12:30 PM | A3. Oncopathology: Diagnosing cancer Paul van Diest, University Medical Center Utrecht, NL |
| 12:30 PM - 1:30 PM | Lunch |
| 1:30 PM - 2:45 PM | A4. Essentials of medical oncology Jan Vermorken, Antwerp Univeristy Hospital, BE |
| 2:45 PM - 4:00 PM | A5. Essentials of hemato-oncology Sanne Tonino, Academic Medical Center Amsterdam, NL |
| 4:00 PM - 4:30 PM | Afternoon Break |
| 4:30 PM - 5:45 PM | A6. Essentials of cancer immunotherapy Christian Blank, Netherlands Cancer Institute, NL |
| 5:45 PM - 6:00 PM | Q&A day 1 overall / Evaluation day 1 |
| 6:00 PM - 7:00 PM | Welcome drinks (complimentary drinks in hotel bar) |
Part B | |
|---|---|
| 9:00 AM - 9:45 AM | B1. Drug discovery and preclinical drug testing Michel Janicot, JMi ONConsulting, BE |
| 9:45 AM - 10:30 AM | B2. Preclinical toxicology of anticancer agents (including introduction group exercise) Benno Rattel, Amgen, DE |
| 10:30 AM - 11:15 AM | Group exercise preclinical toxicology (coffee served) Moderator: Benno Rattel |
| 11:15 AM - 12:30 PM | B3. Phase I clinical studies with single agents (including introduction group exercise) Ferry Eskens, Erasmus University Medical Center, NL |
| 12:30 PM - 1:15 PM | Lunch Thursday |
| 1:15 PM - 2:00 PM | Group exercise phase I studies Plenary discussion of group exercise phase I studies Moderator: Rob Berg |
| 2:00 PM - 3:00 PM | B4. Phase I clinical studies with combinations of agents Anna Minchom, Royal Marsden Hospital & The Institute of Cancer Research, UK |
| 3:00 PM - 3:20 PM | Afternoon Break Thursday |
| 3:20 PM - 4:10 PM | B5. Biomarkers in oncology drug development Alain van Gool, Radboud University Medical Center, NL |
| 4:10 PM - 5:00 PM | B6. Development of companion diagnostics for cancer therapeutics Martina Kaufmann, Martina Kaufmann Strategic Consulting, DE |
| 5:00 PM - 5:20 PM | Q&A sessions B4 & B5 Alain van Gool & Martina Kaufmann |
| 5:20 PM - 5:30 PM | Q&A day 2 overall / Evaluation day 2 |
Part B | |
|---|---|
| 9:00 AM - 10:00 AM | B7. The regulatory environment for anticancer drug development Adriaan Fruijtier, Regulatory Affairs, CATS Consultants, DE |
| 10:00 AM - 10:30 AM | B8.1 Biostatistical considerations in oncology clinical trials (Part 1): Early-phase trials Lucinda Billingham, Cancer Research UK Clinical Trials Unit, UK |
| 10:30 AM - 10:55 AM | Morning Break Friday |
| 10:55 AM - 11:40 AM | B8.1 Biostatistical considerations in oncology clinical trials (Part 2): Late-phase trials Lucinda Billingham, Institute for Cancer and Genomic Sciences, University of Birmingham, UK |
| 11:40 AM - 12:25 PM | B10.1 Full clinical development of cancer therapeutics (including introduction group exercise) Eric van der Putten, Aglaia Biomedical Ventures, NL |
| 12:25 PM - 1:25 PM | Lunch Friday |
| 1:25 PM - 2:10 PM | B10.2 Full clinical development of cancer therapeutics (including introduction group exercise) Eric van der Putten, Aglaia Biomedical Ventures, NL |
| 2:10 PM - 2:20 PM | Afternoon Break Friday |
| 2:20 PM - 3:20 PM | Group exercise full clinical development Moderator: Eric van der Putten |
| 3:20 PM - 3:45 PM | Closing: Take home messages & overall evaluation |